Immunogen Inc (DELISTED) (IMGN:DL)
31.23
0.00 (0.00%)
USD |
NASDAQ |
Feb 13, 16:00
Price Chart
Key Stats
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.1284 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. |
URL | https://www.immunogen.com |
Investor Relations URL | https://investor.immunogen.com |
HQ State/Province | Massachusetts |
Sector | |
Industry | |
Equity Style | Small Cap/Growth |
Next Earnings Release | Mar. 01, 2024 (est.) |
Last Earnings Release | Nov. 02, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. |
URL | https://www.immunogen.com |
Investor Relations URL | https://investor.immunogen.com |
HQ State/Province | Massachusetts |
Sector | |
Industry | |
Equity Style | Small Cap/Growth |
Next Earnings Release | Mar. 01, 2024 (est.) |
Last Earnings Release | Nov. 02, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |